Upregulation of PODXL and ITGB1 in pancreatic cancer tissues preoperatively obtained by EUS-FNAB correlates with unfavorable prognosis of postoperative pancreatic cancer patients

Taniuchi, Keisuke; Ueno, Makoto; Yokose, Tomoyuki; Sakaguchi, Masahiko; Yoshioka, Reiko; Ogasawara, Masahito; Kosaki, Takuhiro; Naganuma, Seiji; Furihata, Mutsuo

doi:10.1371/journal.pone.0265172

Cited by 2 publications

(1 citation statement)

References 34 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UCHL1, Ubiquitin C-Terminal Hydrolase L1, which has been extensively studied in tumors such as lung and breast cancer as well as colorectal cancer ( Yang et al, 2022 ), plays a catalytic role in colorectal cancer ( Zhong et al, 2012 ). PODXL, whose overexpression promotes pancreatic cancer development ( Taniuchi et al, 2022 ); TGF and its mediated PODXL, like the previously mentioned genes, play corresponding roles in colorectal cancer. Patients with radiotherapy-resistant colorectal cancer may benefit from treatment interventions targeting TGF inhibition and PODXL activation ( Lee et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Subtypes analysis and prognostic model construction based on lysosome-related genes in colon adenocarcinoma

Yang

Huang

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: Lysosomes are essential for the development and recurrence of cancer. The relationship between a single lysosome-related gene and cancer has previously been studied, but the relationship between the lysosome-related genes (LRGs) and colon adenocarcinoma (COAD) remains unknown. This research examined the role of lysosome-related genes in colon adenocarcinoma.Methods: 28 lysosome-related genes associated with prognosis (PLRGs) were found by fusing the gene set that is differently expressed between tumor and non-tumor in colon adenocarcinoma with the gene set that is related to lysosomes. Using consensus unsupervised clustering of PLRGs, the colon adenocarcinoma cohort was divided into two subtypes. Prognostic and tumor microenvironment (TME) comparisons between the two subtypes were then made. The PLRGs_score was constructed using the least absolute shrinkage and selection operator regression (LASSO) method to quantify each patient’s prognosis and provide advice for treatment. Lastly, Western Blot and immunohistochemistry (IHC) were used to identify MOGS expression at the protein level in colon adenocarcinoma tissues.Results: PLRGs had more somatic mutations and changes in genetic level, and the outcomes of the two subtypes differed significantly in terms of prognosis, tumor microenvironment, and enrichment pathways. Then, PLRGs_score was established based on two clusters of differential genes in the cancer genome atlas (TCGA) database, and external verification was performed using the gene expression omnibus (GEO) database. Then, we developed a highly accurate nomogram to enhance the clinical applicability of the PLRGs_score. Finally, a higher PLRGs_score was associated with a poorer overall survival (OS), a lower tumor mutation burden (TMB), a lower cancer stem cell (CSC) index, more microsatellite stability (MSS), and a higher clinical stage. MOGS was substantially elevated at the protein level in colon adenocarcinoma as additional confirmation.Conclusion: Overall, based on PLRGs, we identified two subtypes that varied significantly in terms of prognosis and tumor microenvironment. Then, in order to forecast patient prognosis and make treatment suggestions, we developed a diagnostic model with major significance for prognosis, clinical relevance, and immunotherapy. Moreover, we were the first to demonstrate that MOGS is highly expressed in colon adenocarcinoma.

show abstract